Ije Nwokori Purchases 197 Shares of Dr. Martens (LON:DOCS) Stock

Dr. Martens plc (LON:DOCS) insider Ije Nwokori bought 197 shares of the stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of GBX 76 per share, with a total value of £149.72.

Ije Nwokori also recently made the following trade(s):

• On Tuesday, November 11th, Ije Nwokori purchased 176 shares of Dr. Martens stock. The shares were bought at an average cost of GBX 85 per share, for a total transaction of £149.60.
• On Wednesday, October 15th, Ije Nwokori sold 298,675 shares of Dr. Martens stock. The stock was sold at an average price of GBX 90, for a total value of £268,807.50.
• On Monday, October 13th, Ije Nwokori acquired 167 shares of Dr. Martens stock. The stock was purchased at an average cost of GBX 89 per share, with a total value of £148.63.
• On Wednesday, October 8th, Ije Nwokori acquired 136 shares of Dr. Martens stock. The shares were purchased at an average price of GBX 90 per share, for a total transaction of £122.40.

Dr. Martens Trading Up 0.0%

LON DOCS opened at GBX 76.97 on Friday. The stock has a market cap of £743.81 million, a P/E ratio of 45.28, a PEG ratio of 6.40 and a beta of 0.11. The company’s fifty day simple moving average is GBX 84.81 and its 200-day simple moving average is GBX 82.63. The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. Dr. Martens plc has a 52 week low of GBX 43.02 and a 52 week high of GBX 100.87.

Dr. Martens (LON:DOCS) last released its quarterly earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. Equities research analysts predict that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on DOCS shares. Peel Hunt reaffirmed a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Berenberg Bank restated a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 27th. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Dr. Martens has a consensus rating of “Moderate Buy” and an average price target of GBX 6,000.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.